News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
LEONHARDT HARRY J
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/02/2023 |
4
| LEONHARDT HARRY J (GC & Chief Compliance Officer) has filed a Form 4 on Poseida Therapeutics, Inc.|
Txns:
| Granted 92,772 shares
@ $0
Paid exercise price by delivering 4,323 shares
@ $5.35, valued at
$23.1k
Granted 125,283 options to buy
@ $5.35, valued at
$670.3k
|
|
| 03/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/22/2020 |
3
| LEONHARDT HARRY J (GC & Chief Compliance Officer) has filed a Form 3 on Poseida Therapeutics, Inc. |
| 04/15/2019 |
4
| LEONHARDT HARRY J (SVP, GC) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Paid exercise price by delivering 2,377 shares
@ $16.54, valued at
$39.3k
Exercised 6,875 restricted stock units
@ $0 |
|
| 02/22/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/14/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2018 |
4
| LEONHARDT HARRY J (SVP, GC and CCO) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Paid exercise price by delivering 2,377 shares
@ $19.37, valued at
$46k
Exercised 6,875 restricted stock units
@ $0 |
|
| 02/23/2018 |
4
| LEONHARDT HARRY J (SVP, GC and CCO) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Paid exercise price by delivering 3,939 shares
@ $19.28, valued at
$75.9k
Exercised 11,392 restricted stock units
@ $0 |
|
| 02/16/2018 |
4
| LEONHARDT HARRY J (SVP, GC and CCO) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Granted 54,780 options to buy
@ $18.41, valued at
$1M
Granted 31,234 restricted stock units
@ $0 |
|
| 02/05/2018 |
4
| LEONHARDT HARRY J (SVP, GC and CCO) has filed a Form 4 on HALOZYME THERAPEUTICS INC|
Txns:
| Paid exercise price by delivering 5,605 shares
@ $18.37, valued at
$103k
Exercised 15,413 restricted stock units
@ $0 |
|
| 04/14/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/24/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/06/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 04/14/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 08/10/2012 |
4
| LEONHARDT HARRY J (SVP, Legal, Compl & Corp Secty) has filed a Form 4 on AMYLIN PHARMACEUTICALS INC|
Txns:
| Disposed of 32,345 shares
@ $31, valued at
$1M
Disposed of 6,361 shares
@ $31, valued at
$197.2k
Disposed of 727 shares
@ $31, valued at
$22.5k
Disposed of 3,159 shares
@ $31, valued at
$97.9k
Disposed of 4,227 shares
@ $31, valued at
$131k
Disposed of 7,814 options to buy
@ $9.02, valued at
$70.5k
Disposed of 8,614 options to buy
@ $15.03, valued at
$129.5k
Disposed of 9,552 options to buy
@ $16.02, valued at
$153k
Disposed of 6,437 options to buy
@ $18.01, valued at
$115.9k
Disposed of 1,253 options to buy
@ $24.87, valued at
$31.2k
Unknown transaction of 8,360 options to buy
@ $47.83, valued at
$399.9k
|
|
| 03/07/2012 |
4
| LEONHARDT HARRY J (SVP, Legal, Compliance and Cor) has filed a Form 4 on AMYLIN PHARMACEUTICALS INC|
Txns:
| Granted 15,000 shares
@ $0
Granted 1,529 shares
@ $0
Granted 9,552 options to buy
@ $16.02, valued at
$153k
Granted 90,448 options to buy
@ $16.02, valued at
$1.4M
|
|
| 03/02/2012 |
4
| LEONHARDT HARRY J (SVP, Legal, Compliance and Cor) has filed a Form 4 on AMYLIN PHARMACEUTICALS INC|
Txns:
| Sold 1,231 shares
@ $17.11, valued at
$21.1k
|
|
| 02/24/2012 |
4
| LEONHARDT HARRY J (SVP, Legal, Compliance and Cor) has filed a Form 4 on AMYLIN PHARMACEUTICALS INC|
Txns:
| Granted 5,800 shares
@ $0
Sold 2,180 shares
@ $17.0302, valued at
$37.1k
|
|
| 06/09/2010 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|